SCHEMBL5743890

SCHEMBL5743890

Cc1cc(Cl)nc2c1NC(=O)c1cc(Br)cnc1N2C1CC1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
MAPK1 P28482 1/20 0.47
ADORA2A P29274 1/20 0.47
ADORA1 P30542 1/20 0.47
PDE3A Q14432 1/20 0.47
CYP3A4 P08684 3/20 0.46
CYP2C9 P11712 3/20 0.46
CYP2C19 P33261 3/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2D6 P10635 2/20 0.46
OPRK1 P41145 1/20 0.32
CES1 P23141 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5744582 0.83 CYP3A4 (0.51) ALDH1A1LMNAPOLBADORA3MAPK1
SCHEMBL5745099 0.82 CYP3A4 (0.51) ALDH1A1LMNAPOLBADORA3MAPK1
SCHEMBL8304966 0.82 ALDH1A1 (0.72) ALDH1A1LMNAPOLBADORA3MAPK1
SCHEMBL8889576 0.73 ALDH1A1 (0.72) ALDH1A1LMNAPOLBADORA3MAPK1
SCHEMBL8299578 0.73 ALDH1A1 (0.46) ALDH1A1LMNAPOLBADORA3MAPK1
SCHEMBL8301125 0.73 ALDH1A1 (0.46) ALDH1A1LMNAPOLBADORA3MAPK1
SCHEMBL5746280 0.71 CYP3A4 (0.51) ALDH1A1LMNAPOLBADORA3MAPK1
SCHEMBL6717805 0.70 ALDH1A1 (0.70) ALDH1A1LMNAPOLBADORA3MAPK1
SCHEMBL8887731 0.70 ALDH1A1 (0.73) ALDH1A1LMNAPOLBADORA3MAPK1
SCHEMBL8887408 0.69 ALDH1A1 (0.72) ALDH1A1LMNAPOLBADORA3MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1655300-A1 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2006-05-10 EP disclosed
EP-1294720-B1 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS BOEHRINGER INGELHEIM CA LTD (CA) 2006-04-05 EP disclosed
US-6420359-B1 5,11-Dihydro-11-ethyl-5-methyl-8-(2-((1-oxido-4-quinolinyl)oxy)ethyl)-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one for example; antiviral agents for HIV infection BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-07-16 US disclosed
US-20020028807-A1 Non-nucleoside reverse transcriptase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2002-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020028807-A1 Non-nucleoside reverse transcriptase inhibitors REV1, POLR2H, POLR2E ALDH1A1 1770/4885LMNA 3364/4885POLB 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.